Log in

Relevant bibliographies by topics / MLC601 / Journal articles

To see the other types of publications on this topic, follow the link: MLC601.

Journal articles on the topic 'MLC601'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'MLC601.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tan, Chai-Hoon Nowel, David Choy, and Narayanaswamy Venketasubramanian. "NeuroAid II (MLC901) in Haemorrhagic Stroke." Case Reports in Neurology 12, Suppl. 1 (2020): 212–17. http://dx.doi.org/10.1159/000508588.

Full text

Abstract:

Stroke is a leading cause of death and disability. NeuroAid (MLC601), which originates from Traditional Chinese Medicine, comprises herbal and animal components, and has been shown to improve the functional status of patients after ischaemic stroke. The use of NeuroAid II (MLC901), which comprises only the herbal components of MLC601, in haemorrhagic stroke has not been previously reported. Our patient is a 63-year-old male with a significant stroke risk factor of hypertension. He developed visual field defect, aphasia, unilateral weakness, and hemisensory loss. CT scan showed a left thalamic

APA, Harvard, Vancouver, ISO, and other styles

2

Navarro, Jose C., Mark C. Molina, Alejandro C. Baroque II, and Johnny K. Lokin. "The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients." Rehabilitation Research and Practice 2012 (2012): 1–5. http://dx.doi.org/10.1155/2012/506387.

Full text

Abstract:

Aim. We aimed to assess the efficacy of MLC601 on functional recovery in patients given MLC601 after an ischemic stroke.Methods. This is a retrospective cohort study comparing poststroke patients given open-label MLC601 (; 9 female) for three months and matching patients who did not receive MLC601 from our Stroke Data Bank. Outcome assessed was modified Rankin Scale (mRS) at three months and analyzed according to: (1) achieving a score of 0-2, (2) achieving a score of 0-1, and (3) mean change in scores from baseline.Results. At three months, 21 patients on MLC601 became independent as compared

APA, Harvard, Vancouver, ISO, and other styles

3

Al Fauzi, Asra, Krisna Tsaniadi Prihastomo, I. G. M. Aswin R. Ranuh, et al. "Clinical Outcomes of MLC601 (NeuroAiDTM) in Traumatic Brain Injury: A Pilot Study." Brain Sciences 10, no. 2 (2020): 60. http://dx.doi.org/10.3390/brainsci10020060.

Full text

Abstract:

Background: MLC601 is a natural product formulation from Chinese medicine that is extensively studied in ischemic stroke. Traumatic brain injury (TBI) shares pathophysiological mechanisms with ischemic stroke, yet there are few studies on the use of MLC601 in treating TBI. This Indonesian pilot study aimed to investigate clinical outcomes of MLC601 for TBI. Methods: This randomized controlled trial included subjects with nonsurgical moderate TBI allocated into two groups: with and without MLC601 over three months in addition to standard TBI treatment. Clinical outcomes were measured by the Gla

APA, Harvard, Vancouver, ISO, and other styles

4

Pakdaman, Hossein, Ali Amini Harandi, Mehdi Abbasi, et al. "Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study." Dementia and Geriatric Cognitive Disorders Extra 7, no. 1 (2017): 136–42. http://dx.doi.org/10.1159/000458521.

Full text

Abstract:

Background and Aim: Mild cognitive impairment (MCI) is characterized by declined cognitive function greater than that expected for a person’s age. The clinical significance of this condition is its possible progression to dementia. MLC601 is a natural neuroprotective medication that has shown promising effects in Alzheimer disease. Accordingly, we conducted this randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MLC601 in MCI patients. Methods: Seventy-two patients with a diagnosis of MCI were recruited. The included participants were randomly assigned to

APA, Harvard, Vancouver, ISO, and other styles

5

Venketasubramanian, Narayanaswamy, Yogesh Pokharkar, Jia Hui Chai, and Christopher Li Hsian Chen. "Ischemic Stroke and Savings in Time to Achieve Functional Recovery: Experience from NeuroAiD." Journal of Cardiovascular Development and Disease 10, no. 3 (2023): 117. http://dx.doi.org/10.3390/jcdd10030117.

Full text

Abstract:

Despite recent progress with revascularisation interventions after acute ischemic stroke, many patients remain disabled after stroke. Using data from a multi-centre, randomised, double-blind, placebo-controlled trial of a neuro-repair treatment (NeuroAiD/MLC601) with a long-term follow-up, we analysed the savings in time to functional recovery, measured by a modified Rankin Scale (mRS) score of 0 or 1, in patients receiving a 3-month oral course of MLC601. Analysis of time to recovery was assessed by a log-rank test and hazard ratios (HRs) adjusted for prognosis factors. A total of 548 patient

APA, Harvard, Vancouver, ISO, and other styles

6

Pakdaman, Hossein, Ali Amini Harandi, Hamidreza Hatamian, et al. "Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial." Dementia and Geriatric Cognitive Disorders Extra 5, no. 1 (2015): 96–106. http://dx.doi.org/10.1159/000375295.

Full text

Abstract:

Background: MLC601 is a possible modulator of amyloid precursor protein processing, and in a clinical trial study MLC601 showed some effectiveness in cognitive function in Alzheimer's disease (AD) patients. We aimed to evaluate the effectiveness and safety of MLC601 in the treatment of mild to moderate AD as compared to 3 approved cholinesterase inhibitors (ChEIs) including donepezil, rivastigmine and galantamine. Methods: In a multicenter, nonblinded, randomized controlled trial, 264 volunteers with AD were randomly divided into 4 groups of 66; groups 1, 2, 3 and 4 received donepezil, rivasti

APA, Harvard, Vancouver, ISO, and other styles

7

Suwanwela, Nijasri C., Christopher L. H. Chen, Chun Fan Lee, et al. "Effect of Combined Treatment with MLC601 (NeuroAiDTM) and Rehabilitation on Post-Stroke Recovery: The CHIMES and CHIMES-E Studies." Cerebrovascular Diseases 46, no. 1-2 (2018): 82–88. http://dx.doi.org/10.1159/000492625.

Full text

Abstract:

Background and Purpose: MLC601 has been shown in preclinical studies to enhance neurorestorative mechanisms after stroke. The aim of this post hoc analysis was to assess whether combining MLC601 and rehabilitation has an effect on improving functional outcomes after stroke. Methods: Data from the CHInese Medicine NeuroAiD Efficacy on Stroke (CHIMES) and CHIMES-Extension (CHIMES-E) studies were analyzed. CHIMES-E was a 24-month follow-up study of subjects included in CHIMES, a multi-centre, double-blind placebo-controlled trial which randomized subjects with acute ischemic stroke, to either MLC

APA, Harvard, Vancouver, ISO, and other styles

8

Venketasubramanian, Narayanaswamy, Rajesh B. Moorakonda, Qingshu Lu, and Christopher L. H. Chen. "Frequency and Clinical Impact of Serious Adverse Events on Post-Stroke Recovery with NeuroAiD (MLC601) versus Placebo: The CHInese Medicine Neuroaid Efficacy on Stroke Recovery Study." Cerebrovascular Diseases 49, no. 2 (2020): 192–99. http://dx.doi.org/10.1159/000506070.

Full text

Abstract:

Background: Most comparative clinical trials are designed to assess the treatment effect for efficacy endpoints, with less emphasis on the analysis of safety outcomes. However, an extensive analysis of safety data could demonstrate beneficial results in terms of effectiveness by reducing serious adverse events (SAEs), and their unfavourable clinical impact on the study population. We aimed to conduct an exploratory analysis of the CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study safety database comparing the frequency of SAEs and their clinical impacts among subjects having

APA, Harvard, Vancouver, ISO, and other styles

9

SALEH, ARMAN YURISALDI, Riezky Valentina, Tirta Darmawan Susanto, and Dwi Arwandi Yogi Saputra. "Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study." F1000Research 13 (July 16, 2024): 799. http://dx.doi.org/10.12688/f1000research.152581.1.

Full text

Abstract:

Introduction NeuroAiD, also known as MLC601 or MLC901, is a Chinese herbal combination used worldwide for stroke treatment. It contains herbal components and five hewan components. MLC601 contains herbal components and hewan components, while MLC901 has a similar herbal composition. NeuroAiD is used to support neurologic recovery after stroke and to aid cognitive function in Alzheimer’s disease. Studies show that NeuroAiD has potential in treating Alzheimer’s disease and is beneficial in both local and global stroke models and in the Kortikal culture. However, there is limited bibliometric res

APA, Harvard, Vancouver, ISO, and other styles

10

Harandi, A. A., R. Abolfazli, A. Hatemian, et al. "Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial." Stroke Research and Treatment 2011 (2011): 1–5. http://dx.doi.org/10.4061/2011/721613.

Full text

Abstract:

Objective. To investigate the safety and efficacy of MLC601 (NeuroAid) as a traditional Chinese medicine on motor recovery after ischemic stroke.Methods. This study was a double-blind, placebo-controlled clinical trial on 150 patients with a recent (less than 1 month) ischemic stroke. All patients were given either MLC601 (100 patients) or placebo (50 patients), 4 capsules 3 times a day, as an add-on to standard stroke treatment for 3 months.Results. Sex, age, elapsed time from stroke onset, and risk factors in the treatment group were not significantly different from placebo group at baseline

APA, Harvard, Vancouver, ISO, and other styles

11

Pakdaman, Hossein, Koroush Gharagozli, Mehdi Abbasi, et al. "Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study." Dementia and Geriatric Cognitive Disorders Extra 8, no. 1 (2018): 174–79. http://dx.doi.org/10.1159/000488482.

Full text

Abstract:

Background and Aim: Alzheimer disease (AD) is the most common cause of dementia. Currently, there is no disease-modifying therapy for AD. We aimed to evaluate the long-term efficacy and safety of MLC601 in the treatment of AD. Methods: In this open-label extension study, patients with mild to moderate AD according to DSM-IV criteria were recruited. Patients received MLC601 capsules 3 times a day for 4 years. Cognitive function was assessed every 6 months using Mini-Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores. Safety profiles, in

APA, Harvard, Vancouver, ISO, and other styles

12

Venketasubramanian, Narayanaswamy, Chun Fan Lee, Sherry H. Young, et al. "Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery - Extension Study." Cerebrovascular Diseases 43, no. 1-2 (2016): 36–42. http://dx.doi.org/10.1159/000452285.

Full text

Abstract:

Background: The Chinese Medicine NeuroAiD Efficacy on Stroke recovery - Extension (CHIMES-E) study is among the few acute stroke trials with long-term outcome data. We aimed to evaluate the recovery pattern and the influence of prognostic factors on treatment effect of MLC601 over 2 years. Methods: The CHIMES-E study evaluated the 2 years outcome of subjects aged ≥18 years with acute ischemic stroke, National Institutes of Health Stroke Scale (NIHSS) score 6-14, pre-stroke modified Rankin Scale (mRS) score ≤1 included in a multicenter, randomized, double-blind, placebo-controlled trial of MLC6

APA, Harvard, Vancouver, ISO, and other styles

13

Dedy Chandra Hariyono, Hanis Setyono та Ida Bagus Budhi Surya Adnyana. "The Efficacy of NeuroAid™ (MLC601) in Modulating NF-κB Expression and Improving Outcomes in Traumatic Brain Injury: A Preclinical Study". Bioscientia Medicina : Journal of Biomedicine and Translational Research 9, № 6 (2025): 7728–40. https://doi.org/10.37275/bsm.v9i6.1309.

Full text

Abstract:

Background: Traumatic brain injury (TBI) represents a significant global health concern, leading to substantial mortality and long-term disability. The intricate pathophysiology of TBI involves primary mechanical damage followed by a cascade of secondary injury events, including neuroinflammation, apoptosis, and oxidative stress. The nuclear factor kappa B (NF-κB) signaling pathway plays a pivotal role in orchestrating the inflammatory response post-TBI and has emerged as a potential therapeutic target. This preclinical study aimed to investigate the efficacy of NeuroAid™ (MLC601), a tradition

APA, Harvard, Vancouver, ISO, and other styles

14

Dib, Michel, Ihsan Zahra, Siwaporn Chankrachang, et al. "NeuroAiDTM (MLC601, MLC901): A New Bench-to-Bedside Approach to the Treatment of Ischemic Brain Injury." European Journal of Medicinal Plants 5, no. 2 (2015): 117–26. http://dx.doi.org/10.9734/ejmp/2015/13192.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Heurteaux, C., C. Gandin, M. Borsotto, et al. "Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo." Neuropharmacology 58, no. 7 (2010): 987–1001. http://dx.doi.org/10.1016/j.neuropharm.2010.01.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Navarro, Jose C., Christopher LH Chen, Chun F. Lee, et al. "Durability of the beneficial effect of MLC601 (NeuroAiD™) on functional recovery among stroke patients from the Philippines in the CHIMES and CHIMES-E studies." International Journal of Stroke 12, no. 3 (2016): 285–91. http://dx.doi.org/10.1177/1747493016676615.

Full text

Abstract:

Background and Aim A pre-specified country analysis of subjects from the Philippines in the CHInese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) Study showed significantly improved functional and neurological outcomes on MLC601 at month (M) 3. We aimed to assess these effects on long-term functional recovery in the Filipino cohort. Methods The CHIMES-E (extension) Study evaluated subjects who completed three months of randomized placebo-controlled treatment in CHIMES up to two years. Blinding of treatment allocation was maintained and all subjects received standard stroke care and re

APA, Harvard, Vancouver, ISO, and other styles

17

Ohnmar, Htwe, Ramesh Kumar, Azmi Baharudin, et al. "Safety and efficacy of MLC601/MLC901 (NeuroAiD) amongst patients who sustain severe spinal cord injury (SATURN study)." Journal of the Neurological Sciences 429 (October 2021): 118574. http://dx.doi.org/10.1016/j.jns.2021.118574.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Venketasubramanian, Narayanaswamy, Sherry H. Young, San San Tay, et al. "CHInese Medicine NeuroAiD Efficacy on Stroke Recovery - Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy." Cerebrovascular Diseases 39, no. 5-6 (2015): 309–18. http://dx.doi.org/10.1159/000382082.

Full text

Abstract:

Background: The CHInese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) study was an international randomized double-blind placebo-controlled trial of MLC601 (NeuroAiD) in subjects with cerebral infarction of intermediate severity within 72 h. CHIMES-E (Extension) aimed at evaluating the effects of the initial 3-month treatment with MLC601 on long-term outcome for up to 2 years. Methods: All subjects randomized in CHIMES were eligible for CHIMES-E. Inclusion criteria for CHIMES were age ≥18, baseline National Institute of Health Stroke Scale of 6-14, and pre-stroke modified Rankin Scale

APA, Harvard, Vancouver, ISO, and other styles

19

Venketasubramanian, Narayanaswamy, Tseng Tsai Yeo, and Christopher Li Hsian Chen. "Translational Medicine in Acute Ischemic Stroke and Traumatic Brain Injury—NeuroAiD Trials, from Traditional Beliefs to Evidence-Based Therapy." Biomolecules 14, no. 6 (2024): 680. http://dx.doi.org/10.3390/biom14060680.

Full text

Abstract:

Acute ischemic stroke (AIS) and traumatic brain injury (TBI) are two severe neurological events, both being major causes of death and prolonged impairment. Their incidence continues to rise due to the global increase in the number of people at risk, representing a significant burden on those remaining impaired, their families, and society. These molecular and cellular mechanisms of both stroke and TBI present similarities that can be targeted by treatments with a multimodal mode of action, such as traditional Chinese medicine. Therefore, we performed a detailed review of the preclinical and cl

APA, Harvard, Vancouver, ISO, and other styles

20

Lim, Y. A., L. A. Murray, M. K. P. Lai, and C. Chen. "NeuroAiD®(MLC601) and Amyloid Precursor Protein Processing." Cerebrovascular Diseases 35, s1 (2013): 30–37. http://dx.doi.org/10.1159/000346236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Kumar, Ramesh, Azizi Abu Bakar, Jegan Thanabalan, et al. "Safety and Use of MLC601/MLC901 (NeuroAiDTM) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry." Brain Sciences 10, no. 8 (2020): 499. http://dx.doi.org/10.3390/brainsci10080499.

Full text

Abstract:

Background: MLC601/MLC901 (NeuroAiD™) is a combination of natural products shown to be safe and to aid neurological recovery after brain injuries, especially ischemic stroke. Few studies have investigated NeuroAiD in primary intracerebral hemorrhage (ICH). The NeuroAiD Safe Treatment (NeST) Registry explores NeuroAiD use in the real-world setting. This cohort study aimed to assess its use and safety in ICH. Methods: The online NeST Registry of subjects with ICH given NeuroAiD prospectively collected clinical data at baseline and monthly visits (V) 1 to 3. Outcome measures included compliance,

APA, Harvard, Vancouver, ISO, and other styles

22

Quintard, Hervé, Marc Borsotto, Catherine Widmann, Carine Gandin, Michel Lazdunski, and Catherine Heurteaux. "MLC601/MLC901, issu de la médecine chinoise induit de puissantes propriétés neuroprotectrices et neurorégénératives face à l’ischémie cérébrale chez le rongeur." Revue Neurologique 168 (April 2012): A126. http://dx.doi.org/10.1016/j.neurol.2012.01.322.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Pakdaman, Hossein, Ali Amini Harandi, Koroush Gharagozli, et al. "MLC601 in vascular dementia: an efficacy and safety pilot study." Neuropsychiatric Disease and Treatment Volume 13 (October 2017): 2551–57. http://dx.doi.org/10.2147/ndt.s145047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Chen, Christopher L. H., Narayanaswamy Venketasubramanian, Chun Fan Lee, et al. "Effects of MLC601 on Early Vascular Events in Patients After Stroke." Stroke 44, no. 12 (2013): 3580–83. http://dx.doi.org/10.1161/strokeaha.113.003226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Chen, C., N. Venketasubramanian, C. F. Lee, K. S. L. Wong, and M. G. Bousser. "Effects of MLC601 on early recurrent vascular events in post-stroke patients —/INS; The chimes study." Journal of the Neurological Sciences 333 (October 2013): e277. http://dx.doi.org/10.1016/j.jns.2013.07.1056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Siddiqui, Fahad Javaid, Narayanaswamy Venketasubramanian, Edwin Shih-Yen Chan, and Christopher Chen. "Efficacy and Safety of MLC601 (NeuroAiD®), a Traditional Chinese Medicine, in Poststroke Recovery: A Systematic Review." Cerebrovascular Diseases 35, s1 (2013): 8–17. http://dx.doi.org/10.1159/000346231.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

González-Fraile, Eduardo, Manuel Martín-Carrasco, and Javier Ballesteros. "Efficacy of MLC601 on functional recovery after stroke: A systematic review and meta-analysis of randomized controlled trials." Brain Injury 30, no. 3 (2016): 267–70. http://dx.doi.org/10.3109/02699052.2015.1118764.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Venketasubramanian, Narayanaswamy, Chun Fan Lee, K. S. Lawrence Wong, and Christopher L. H. Chen. "The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD)." Journal of Evidence-Based Medicine 8, no. 3 (2015): 149–53. http://dx.doi.org/10.1111/jebm.12170.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Ratz, P. H. "Receptor activation induces short-term modulation of arterial contractions: memory in vascular smooth muscle." American Journal of Physiology-Cell Physiology 269, no. 2 (1995): C417—C423. http://dx.doi.org/10.1152/ajpcell.1995.269.2.c417.

Full text

Abstract:

This study examined the hypothesis that arteries retain a memory of receptor activation, resulting in temporary modulation of stimulus-contraction coupling. When pretreated for 30 min with 10(-5) M phenylephrine (PE), histamine, or prostaglandin F2 alpha (PGF2 alpha) and then relaxed fully for 10 min, steady-state increases in stress (S/So) and myosin light-chain phosphorylation (MLC20P/MLC20) produced by KCl in femoral arteries were weaker (0.33-0.57 S/So and 0.29-0.30 MLC20P/MLC20) than control responses (approximately 0.91 S/So and approximately 0.41 MLC20P/MLC20). The inhibitory effect las

APA, Harvard, Vancouver, ISO, and other styles

30

Bavarsad Shahripour, Reza, Gholamreza Shamsaei, Hosein Pakdaman, et al. "The effect of NeuroAiD™ (MLC601) on cerebral blood flow velocity in subjects' post brain infarct in the middle cerebral artery territory." European Journal of Internal Medicine 22, no. 5 (2011): 509–13. http://dx.doi.org/10.1016/j.ejim.2011.01.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Young, Sherry H. Y., Yudong Zhao, Angeline Koh, et al. "Safety Profile of MLC601 (Neuroaid®) in Acute Ischemic Stroke Patients: A Singaporean Substudy of the Chinese Medicine Neuroaid Efficacy on Stroke Recovery Study." Cerebrovascular Diseases 30, no. 1 (2010): 1–6. http://dx.doi.org/10.1159/000313398.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Harandi, Ali. "Efficacy and Tolerability of MlC601 in Patients with Mild to Moderate Alzheimer Disease who were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine." British Journal of Medicine and Medical Research 3, no. 2 (2013): 341–50. http://dx.doi.org/10.9734/bjmmr/2013/2537.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Huang, Suhua, Mingxia Lin, Xiaowei Pan, Qiwen Tan, and Kai-Leng Tan. "The potential of MLC901 (NeuroAiD II™), a traditional Chinese medicine." Neuroscience Research Notes 2, no. 2 (2019): 18–24. http://dx.doi.org/10.31117/neuroscirn.v2i2.32.

Full text

Abstract:

Stroke, also known as cerebral ischemia, is a common neurological disease. The therapeutic potential of MLC901 (NeuroAiD II™) has been reported in clinical trials on traumatic brain injury as well as in animal and cell models. MLC901 reduced the infarction size, ischemia-induced neurological deficits and pro-inflammatory infiltration of phagocyte. It also inhibited the ischemia-induced expression of pro-inflammatory mediators and Prx6, TLR4 signalling, and phosphorylation of NFκB. We found that the beneficial effects of MLC901 are in coherent with studies performed on the individual active ing

APA, Harvard, Vancouver, ISO, and other styles

34

Samadov, F. M., and T. Sh Jahangirov. "PATENT FORAMEN OVALE AND RELATED NEUROLOGICAL DISEASES." National Journal of Neurology 1, no. 24 (2024): 10–17. https://doi.org/10.61788/njn.v1i24.01.

Full text

Abstract:

Background. Traumatic Brain Injury (TBI) results in acute and chronic sequalae involving structural and functional impairments especially in children. This leads to significant disability, which affects child’s development and adaptive functions. Elderly patients and children have a high risk of developing long-term disability, which have no proven treatments. MLC901 (NeuroAiDTM II) is a combination of natural herbal formulations with origins from Traditional Chinese Medicine which has shown to be safe and aids in neurological recovery after brain injuries. Objective. There is an existing know

APA, Harvard, Vancouver, ISO, and other styles

35

Kho, G. S. "CLINICAL EXPERIENCE OF THERAPEUTIC BENEFIT OF NEUROAID^TM (MLC901) IN PEDIATRICS: REVIEW OF THREE CASES OF SEVERE TRAUMATIC BRAIN INJURY." National Journal of Neurology 1, no. 24 (2024): 68–75. https://doi.org/10.61788/njn.v1i24.11.

Full text

Abstract:

Background. Traumatic Brain Injury (TBI) results in acute and chronic sequalae involving structural and functional impairments especially in children. This leads to significant disability, which affects child’s development and adaptive functions. Elderly patients and children have a high risk of developing long-term disability, which have no proven treatments. MLC901 (NeuroAiDTM II) is a combination of natural herbal formulations with origins from Traditional Chinese Medicine which has shown to be safe and aids in neurological recovery after brain injuries. Objective. There is an existing know

APA, Harvard, Vancouver, ISO, and other styles

36

Gandin, Carine, Catherine Widmann, Michel Lazdunski, and Catherine Heurteaux. "MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice." Cerebrovascular Diseases 42, no. 1-2 (2016): 139–54. http://dx.doi.org/10.1159/000444810.

Full text

Abstract:

Background: There is increasing evidence that angiogenesis, through new blood vessel formation, results in improved collateral circulation and may impact the long-term recovery of patients. In this study, we first investigated the preventive action of a 5-week pretreatment of MLC901, an herbal extract preparation derived from Chinese medicine, against the deleterious effects of ischemic stroke and its effects on angiogenesis in a model of focal ischemia in mice. Methods: The stroke model was induced by 60 min of middle cerebral artery occlusion followed by reperfusion. MLC901 was administered

APA, Harvard, Vancouver, ISO, and other styles

37

Nasehi, Maryam, Farshad Ghazalian, Nader Shakeri, Mohammad Nasehi, and Mohammad-Reza Zarrindast. "Influence of MLC901 Alone and with Moderate Exercise on Pain Response Concurrent Due to Stress of Male Mice." Galen Medical Journal 8 (July 10, 2019): 1253. http://dx.doi.org/10.31661/gmj.v8i0.1253.

Full text

Abstract:

Background: Physical exercise is known to have a positive effect on pain responses induced by stress, while chronic stress causes a negative effect on cognitive abilities. Depending on the type, duration, and intensity of the stressor, it can induce analgesia or hyperalgesia. Furthermore, the beneficial effects of traditional Chinese medicine MLC901 on stress processes have been reported. Here, the effects of MLC901 and moderate physical activity on pain response in restraint-stressed mice was investigated. Materials and Methods: Male NMRI mice were used in this study and were restrained in pl

APA, Harvard, Vancouver, ISO, and other styles

38

Arsovska, Anita Ante, and Narayanaswamy Venketasubramanian. "Use of MLC901 in cerebral venous sinus thrombosis: Three case reports." World Journal of Clinical Cases 12, no. 2 (2024): 346–53. http://dx.doi.org/10.12998/wjcc.v12.i2.346.

Full text

Abstract:

BACKGROUND Cerebral venous sinus thrombosis (CVT) is rare cause of cerebrovascular disease. The incidence is 0.5% of all stroke. The majority of affected patients are young adults (mean age: 35-40 years) with mild to moderate disabilities. Poor outcome with severe disability is seen in 13% of cases. Early diagnosis and treatment are important for good outcomes and preventing complications. Treatment options are limited and mostly based on consensus. NeuroAiD II™ (MLC901; Moleac Pte, Ltd, Singapore) has a potential beneficial role in post-stroke recovery, by aiding the natural brain recovery pr

APA, Harvard, Vancouver, ISO, and other styles

39

Wardhana, Dewa Putu Wisnu, Agung Bagus Sista Satyarsa, Rohadi Muhammad Rosyid, et al. "The potential of MLC901 as adjuvant therapy for traumatic spinal cord injury by multi-pathway biomechanism: a systematic review." Bali Medical Journal 12, no. 2 (2023): 2130–41. http://dx.doi.org/10.15562/bmj.v12i2.4606.

Full text

Abstract:

Background: Traumatic spinal cord injury (tSCI) is a severe neurological condition that causes long-term nerve function impairment and can even cause death. Further efforts are needed to find better therapy for this condition to improve patients' quality and life expectancy. Moleac 901 (MLC901) is a phytopharmacological refinement that incorporates important molecules to facilitate progenitor nerve cell amplification and differentiation and has significant neuroprotective effects in tSCI cases. This systematic review aims to discover the potential of MLC901 as adjuvant therapy for traumatic sp

APA, Harvard, Vancouver, ISO, and other styles

40

Ranuh, I. G. M. Aswin R., Gadis Meinar Sari, Budi Utomo, Nur Setiawan Suroto, and Asra Al Fauzi. "Systematic Review and Meta-Analysis of the Efficacy of MLC901 (NeuroAiD IITM) for Acute Ischemic Brain Injury in Animal Models." Journal of Evidence-Based Integrative Medicine 26 (January 1, 2021): 2515690X2110392. http://dx.doi.org/10.1177/2515690x211039219.

Full text

Abstract:

Introduction. Moleac (MLC) 901 is a traditional Chinese medication approved by the Sino Food and Drug Administration in 2001 for treating stroke. This study aims to analyze the efficacy of MLC901 in animal stroke models after medial cerebral artery occlusion (MCAO). Methods. Literature selection was performed according to the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA) 2015. Inclusion criteria for the experimental studies were the use of animal models, publication in English between 1990 and 2020, information regarding the intervention

APA, Harvard, Vancouver, ISO, and other styles

41

Ilham, M. Arya Rifqi, Ilsa Hunaifi, and Bayu Tirta Dirja. "Effect of MLC901 on Red Cell Distribution Width (RDW) in Acute Ischemic Stroke: Literature Review." Jurnal Biologi Tropis 24, no. 2 (2024): 431–40. http://dx.doi.org/10.29303/jbt.v24i2.6833.

Full text

Abstract:

Acute ischemic stroke is an acute episode of neurological dysfunction caused by focal infarction or damage that persists for ≥24 hours in the brain, spine, and retinal. Stroke is the second highest cause of death worldwide. The total prevalence of stroke continues to increase in the world and in Indonesia. However, stroke treatment is still less effective, so adjuvant therapy needs to be developed; one of them is MLC901. However, this therapy still needs to be studied further regarding its effect on acute ischemic stroke and the biomarkers used as the prognostic factors, such as red cell distr

APA, Harvard, Vancouver, ISO, and other styles

42

Chong, Collin, Sian Edney, and Benjamin Jelly. "The Effectiveness of Traditional Chinese Medicine in Treating Alzheimer’s Disease." BJPsych Open 11, S1 (2025): S28—S29. https://doi.org/10.1192/bjo.2025.10112.

Full text

Abstract:

Aims: The prevalence of Alzheimer’s disease (AD) is increasing across the world, yet extensive research has not yielded effective curative treatment. Traditional Chinese Medicine (TCM) has shown benefits and potential in treating AD. However, there were no recent systematic reviews of the different TCM modalities in treating AD specifically. The primary aim of this systematic review (SR) was to investigate the effectiveness of TCM either as a standalone or adjunct treatment alongside conventional medication for AD. The secondary aim was to provide recommendations for treating AD by exploring t

APA, Harvard, Vancouver, ISO, and other styles

43

Anjum, Anam, Muhammad Dain Yazid, Muhammad Fauzi Daud та ін. "NeuroAiDTM-II (MLC901) Promoted Neurogenesis by Activating the PI3K/AKT/GSK-3β Signaling Pathway in Rat Spinal Cord Injury Models". Biomedicines 12, № 8 (2024): 1920. http://dx.doi.org/10.3390/biomedicines12081920.

Full text

Abstract:

Traumatic damage to the spinal cord (SCI) frequently leads to irreversible neurological deficits, which may be related to apoptotic neurodegeneration in nerve tissue. The MLC901 treatment possesses neuroprotective and neuroregenerative activity. This study aimed to explore the regenerative potential of MLC901 and the molecular mechanisms promoting neurogenesis and functional recovery after SCI in rats. A calibrated forceps compression injury for 15 s was used to induce SCI in rats, followed by an examination of the impacts of MLC901 on functional recovery. The Basso, Beattie, and Bresnahan (BB

APA, Harvard, Vancouver, ISO, and other styles

44

Pilipenko, Pavel I., Anna A. Ivanova, Yulia V. Kotsiubinskaya, et al. "A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury." PLOS One 20, no. 7 (2025): e0310229. https://doi.org/10.1371/journal.pone.0310229.

Full text

Abstract:

Introduction About half of the world population will suffer from a traumatic brain injury (TBI) during their lifetime, of which about 90% of cases are mild TBI. Although up to 40% of adults with mild TBI experience persistent functional deficits, there is no proven-effective treatment to facilitate recovery after it. Methods and analysis This randomized placebo-controlled multi-centre study was aimed to examine the efficacy of herbal supplement MLC901 on complex attention following mild TBI at 6 months post-randomisation, as a primary outcome measured by CNS Vital signs (CNS-VS). Adults aged 1

APA, Harvard, Vancouver, ISO, and other styles

45

Pilipenko, Pavel, Anna Andreevna Ivanova, Yulia Vadimovna Kotsiubinskaya, et al. "Randomised, double-blind, placebo-controlled study investigating Safety and efficAcy of MLC901 in post-traUmatic bRAin Injury: the SAMURAI study protocol." BMJ Open 12, no. 4 (2022): e059167. http://dx.doi.org/10.1136/bmjopen-2021-059167.

Full text

Abstract:

IntroductionTraumatic brain injury (TBI) is a leading cause of death in young adults globally and 90% of cases are mild TBI. Treatment to facilitate recovery after TBI is needed. Traditional medicine MLC901 (NeuroAiD II) with neuroprotective and neuroproliferative properties in cellular and animal models of brain injury showed TBI-associated cognitive improvement in mild or moderate TBI.Methods and analysisThis is a randomised placebo-controlled trial, with 6-month treatment and 9-month follow-up, to determine the safety and efficacy of MLC901 in improving cognitive function in patients with c

APA, Harvard, Vancouver, ISO, and other styles

46

Kusuma, Gede Febby Pratama, Sri Maliawan, Tjokorda Gde Bagus Mahadewa, Ni Nyoman Sri Budayanti, Tjokorda Gde Agung Senapathi, and Anak Agung Ayu Putri Laksmidewi. "The effect of MLC901 therapy on neutrophil-to-lymphocyte-ratio, platelet-to-lymphocyte-ratio, BDNF, MoCA-INA score, and Barthel-index score in traumatic brain injury patients." Bali Medical Journal 13, no. 3 (2024): 1040–44. https://doi.org/10.15562/bmj.v13i3.4822.

Full text

Abstract:

Background: An intervention is needed to prevent secondary-brain-injury (SBI) post-traumatic-brain-injury (TBI) and improved the patient’s clinical outcome. Recent pre-clinical studies found that MLC901, a phytopharmaceutical supplement, has the neuroprotective and neuroregenerative potential to prevent SBI post-TBI. This study aimed to clinically prove the neuroprotection and neuroregeneration effects of MLC901 therapy on TBI through the neutrophil-to-lymphocyte-ratio (NLR), platelet-to-lymphocyte-ratio (PLR), BDNF, MoCA-INA score and Barthel-Index (BI) score. Methods: A randomized-control-gr

APA, Harvard, Vancouver, ISO, and other styles

47

Lee, Wei Thye, Christopher Chen Li Hsian, and Yun-An Lim. "The effects of MLC901 on tau phosphorylation." NeuroReport 28, no. 16 (2017): 1043–48. http://dx.doi.org/10.1097/wnr.0000000000000884.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Ratz, Paul H., and Amy S. Miner. "Length-dependent regulation of basal myosin phosphorylation and force in detrusor smooth muscle." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 284, no. 4 (2003): R1063—R1070. http://dx.doi.org/10.1152/ajpregu.00596.2002.

Full text

Abstract:

Urinary bladder (detrusor) smooth muscle is active in the absence of an external stimulus. Tone occurs even “at rest” during the filling phase, and it is elevated in patients with overactive bladder. This study examined the role of muscle length on tone and the level of basal myosin light chain phosphorylation (MLC20P). MLC20P was 23.9 ± 1% ( n = 58) at short lengths (zero preload; L z). An increase in length from L z to the optimal length for contraction ( L o) caused a reduction in MLC20P to 15.8 ± 1% ( n = 49). Whereas 10 μM staurosporine reduced MLC20P at L z, 1 μM staurosporine, a Ca2+-fr

APA, Harvard, Vancouver, ISO, and other styles

49

Gandhi, S., D. D. Lorimer, and P. de Lanerolle. "Expression of a mutant myosin light chain that cannot be phosphorylated increases paracellular permeability." American Journal of Physiology-Renal Physiology 272, no. 2 (1997): F214—F221. http://dx.doi.org/10.1152/ajprenal.1997.272.2.f214.

Full text

Abstract:

A murine leukemia retroviral vector was engineered to contain the DNA encoding either the wild-type, rat aorta 20-kDa myosin light chain (MLC20) or a mutant form of MLC20 in which Thr18 and Ser19 were mutated into alanines. These mutations result in a MLC20 that cannot be phosphorylated by myosin light chain kinase. An 11-amino acid epitope from c-myc was added to both MLC20 sequences to facilitate identification of these proteins. Madin-Darby canine kidney cells were stably transduced, and MLC20 expression was demonstrated by Western blot analysis using a myc-specific antibody. MLC20 exchange

APA, Harvard, Vancouver, ISO, and other styles

50

Fazal, Fabeha, Lianzhi Gu, Ivanna Ihnatovych, et al. "Inhibiting Myosin Light Chain Kinase Induces Apoptosis In Vitro and In Vivo." Molecular and Cellular Biology 25, no. 14 (2005): 6259–66. http://dx.doi.org/10.1128/mcb.25.14.6259-6266.2005.

Full text

Abstract:

ABSTRACT Previous short-term studies have correlated an increase in the phosphorylation of the 20-kDa light chain of myosin II (MLC20) with blebbing in apoptotic cells. We have found that this increase in MLC20 phosphorylation is rapidly followed by MLC20 dephosphorylation when cells are stimulated with various apoptotic agents. MLC20 dephosphorylation is not a consequence of apoptosis because MLC20 dephosphorylation precedes caspase activation when cells are stimulated with a proapoptotic agent or when myosin light chain kinase (MLCK) is inhibited pharmacologically or by microinjecting an inh

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!